TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00234091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: 8 mg/kg (up to 300 mg/dose) take orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: 8 mg/kg (up to 300 mg/dose) take orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 200 to 600 mg taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 200 to 600 mg taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 4 mg/kg (up to 150 mg/dose) taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 4 mg/kg (up to 150 mg/dose) taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelfinavir
Description: 45-55 mg/kg taken orally twice daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelfinavir
Description: 45-55 mg/kg taken orally twice daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
Study: NCT03726268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
Study: NCT03625362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Hydrogen-rich water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap water
Study: NCT01938781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: antiviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: antiviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: antiviral and antifibrosis therapy
Study: NCT02515617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tubes not allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
Study: NCT01057719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
Study: NCT02669160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC Innowalk

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional passive stander
Study: NCT01748955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine CR for Major Depressive Episode
Description: Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL for Major Depressive Episode
Description: Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
Study: NCT02274948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin in the form of 500mg tablets were administer to the Metformin group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
Study: NCT04752098

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vibro-acoustic analysis (VAA), based on ultrasound radiation force
Description: The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
Study: NCT04569786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
Study: NCT02474667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANG-3777

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01008995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subcutaneous injection at Week 0 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: 45 mg subcutaneous injection at Week 12 and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subcutaneous injection at Week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: 45 mg subcutaneous injection at Week 0, 4 and 16
Study: NCT04569786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
Study: NCT03114306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration analgesia
Description: Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional-anaesthesiological catheter analgesia
Description: Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
Study: NCT01773135

Intervention type: OTHER
Intervention: collection of blood sample and tocolysis adminstration
Description: investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone.

Intervention type: OTHER
Intervention: collection of blood sample and tocolysis adminstration
Description: investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone.
Study: NCT02982304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation Electrode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation Electrode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation Electrode
Study: NCT03777722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored Lighting Intervention
Description: Lighting Intervention - active or placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored Lighting Intervention
Description: Lighting Intervention - active or placebo
Study: NCT04136561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline catheter
Description: Midline catheter placed in patients with existing standard of care CVC
Study: NCT03446937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection
Description: Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Sodium Phosphate Injection (Medication)
Description: betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
Study: NCT01280968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIC002 in Aluminum hydroxide (Alum)
Description: Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine - Aluminum hydroxide
Description: Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
Study: NCT03070366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: * cisplatin~* 5FU~* carboplatin~* cetuximab

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiotherapy
Description: Stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic radiotherapy
Study: NCT02343107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-coaching
Description: connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
Study: NCT03726268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
Study: NCT05027178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: Chiropractic care on stroke participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: Chiropractic care on stroke participants
Study: NCT03446937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Two doses of intramuscular injection of water for injection given 12 hours apart
Study: NCT01503476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bravo® pH Monitoring System
Description: Bravo pH monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bravo® pH Monitoring System
Description: Bravo pH monitoring
Study: NCT04146467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renuvion APR Device
Description: The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renuvion APR Device
Description: The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
Study: NCT01442740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg Position
Description: Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
Study: NCT05067062

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: New Zealand blackcurrant extract
Description: Capsules taken daily or intermittent

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Zealand blackcurrant extract
Description: Capsules taken daily or intermittent
Study: NCT00783341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAP-134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03562585

Intervention type: DIAGNOSTIC_TEST
Intervention: with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
Description: with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
Study: NCT00084916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01984034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Outreach Visits
Description: The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Dissemination
Description: Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
Study: NCT01328249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
Study: NCT04569786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V590
Description: Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.
Study: NCT02412774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBs at the end of the main meal + Diet
Description: Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water at the end of the main meal+ Diet
Description: Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
Study: NCT03201224

Intervention type: DEVICE
Intervention: After Group
Study: NCT00488657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeechEasy Model ITC
Description: The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
Study: NCT00202865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
Study: NCT03199235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucky Iron Fish
Description: 200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enhanced standard of care
Description: parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
Study: NCT02771938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy before surgery
Description: Radiotherapy followed by mastectomy and DIEP flap reconstruction
Study: NCT01595906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilated Helmet
Description: The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.